What are the comparative effectiveness and safety profiles of guselkumab and adalimumab for the treatment of plaque psoriasis?

Zenodo (CERN European Organization for Nuclear Research) 2026 Open access

Read full text
Authors: Tripdatabase
DOI: 10.5281/zenodo.18403419
Cited by: 0

Abstract

Guselkumab demonstrates superior efficacy with a comparable safety profile to adalimumab for treating moderate-to-severe plaque psoriasis.

Fields of Study & Subjects

Psoriasis: Treatment and Pathogenesis Dermatology and Skin Diseases Spondyloarthritis Studies and Treatments

Publication details

Journal / source
Zenodo (CERN European Organization for Nuclear Research)
Publication date
28 January 2026